Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NTLA

Intellia Therapeutics Inc

May 10 • 03:14PM ET

24.73

Dollar change -0.13
Percentage change -0.52	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: ARKK VTI VB ARKG IWM VXF VBK IWN IBB SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.37	Insider Own	2.33%	Shs Outstand	96.44M	Perf Week	4.79%
Market Cap	2.38B	Forward P/E	-	EPS next Y	-5.50	Insider Trans	-2.32%	Shs Float	94.19M	Perf Month	-1.12%
Income	-485.50M	PEG	-	EPS next Q	-1.21	Inst Own	84.94%	Short Float	16.39%	Perf Quarter	-12.40%
Sales	52.60M	P/S	45.34	EPS this Y	6.06%	Inst Trans	-0.30%	Short Ratio	10.33	Perf Half Y	-13.08%
Book/sh	10.76	P/B	2.30	EPS next Y	-7.93%	ROA	-36.27%	Short Interest	15.44M	Perf Year	-45.28%
Cash/sh	9.89	P/C	2.50	EPS next 5Y	30.00%	ROE	-43.60%	52W Range	19.37 - 47.48	Perf YTD	-18.89%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-22.30%	ROI	-43.03%	52W High	-47.91%	Beta	1.87
Dividend TTM	-	Quick Ratio	9.03	Sales past 5Y	12.09%	Gross Margin	82.06%	52W Low	27.67%	ATR (14)	1.28
Dividend Ex-Date	-	Current Ratio	9.03	EPS Y/Y TTM	12.31%	Oper. Margin	-1420.51%	RSI (14)	56.32	Volatility	4.86% 5.22%
Employees	526	Debt/Eq	0.11	Sales Y/Y TTM	-1.63%	Profit Margin	-922.94%	Recom	1.54	Target Price	69.39
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	4.25%	Payout	-	Rel Volume	0.91	Prev Close	24.86
Sales Surprise	157.37%	EPS Surprise	18.02%	Sales Q/Q	129.53%	Earnings	May 09 BMO	Avg Volume	1.49M	Price	24.73
SMA20	10.67%	SMA50	-3.36%	SMA200	-16.72%	Trades		Volume	1,211,774	Change	-0.52%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-24	Downgrade	Goldman	Buy → Neutral	$136 → $32
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy	$66
Mar-21-23	Initiated	Bernstein	Outperform	$54
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$54 → $57
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$67
Jan-24-23	Upgrade	Citigroup	Sell → Neutral	$48 → $39
Jan-19-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-11-22	Initiated	Morgan Stanley	Overweight	$84
Sep-21-22	Initiated	JP Morgan	Overweight	$85
Sep-01-22	Initiated	Citigroup	Sell	$50
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$54
Jun-16-22	Initiated	BofA Securities	Buy	$70
Apr-28-22	Initiated	Credit Suisse	Outperform	$100
Feb-18-22	Initiated	William Blair	Outperform	$144
Feb-07-22	Upgrade	Oppenheimer	Perform → Outperform	$145 → $150
Jan-31-22	Initiated	Cowen	Outperform
Jan-07-22	Initiated	Piper Sandler	Overweight	$171
Oct-05-21	Initiated	Guggenheim	Buy	$170
Sep-24-21	Initiated	Stifel	Buy	$173

Show Previous Ratings

Today 01:16PM	Intellia Therapeutics Q1 2024 Earnings: Aligns with Analyst Projections Amidst Strategic Advances (GuruFocus.com)
11:45AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
11:26AM	Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates (Zacks)
May-09-24 11:53PM	Q1 2024 Intellia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +8.09%
11:42AM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
08:49AM	Loading…
08:49AM	Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises (MT Newswires)
08:40AM	Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-03-24 06:15PM	Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today (Zacks)
02:18PM	Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street's Radar (InvestorPlace)
May-02-24 07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates (GlobeNewswire)
06:04AM	3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace)
Apr-29-24 07:30AM	Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024 (GlobeNewswire) +5.88%
Apr-25-24 11:21AM	Intellia (NTLA) to Report Q1 Earnings: What's in the Cards? (Zacks) -5.43%
10:01AM	Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline (Zacks)
05:55AM	Loading…
Apr-14-24 05:55AM	2 Stocks Down 30% to Buy Right Now (Motley Fool)
Apr-12-24 04:50AM	Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week. (Motley Fool)
Apr-09-24 04:50AM	Bull Market and Beyond: 3 Stocks Just Waiting to Soar (Motley Fool)
Mar-28-24 05:55AM	Better Cathie Wood Stock: Moderna vs. Intellia (Motley Fool)
Mar-21-24 05:29PM	Hot Stocks: The 3 Best Opportunities for Investing in Biotech (InvestorPlace)
04:19PM	3 Stocks That Could Be the Next Big Thing in Gene Editing (InvestorPlace)
Mar-19-24 01:06PM	Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study (Zacks)
Mar-18-24 07:30AM	Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy (GlobeNewswire)
Mar-09-24 09:45AM	Is Intellia Therapeutics Stock a Buy Now? (Motley Fool)
Mar-06-24 10:35AM	Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst (Motley Fool)
Mar-01-24 01:43PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
Feb-29-24 05:50AM	A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now (Motley Fool)
Feb-28-24 09:30AM	Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks) +5.74%
Feb-27-24 11:55AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool) +12.15%
09:35AM	Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average (Zacks)
12:22PM	Loading…
Feb-23-24 12:22PM	Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript (Insider Monkey)
11:12AM	Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update (Zacks)
09:55AM	Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High? (Zacks)
Feb-22-24 10:53PM	Q4 2023 Intellia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
08:12AM	Intellia Therapeutics Inc (NTLA) Reports Full-Year 2023 Financial Results and Operational Progress (GuruFocus.com)
07:30AM	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Feb-20-24 05:02AM	Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought (Motley Fool)
Feb-17-24 01:59AM	Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen? (Motley Fool)
Feb-15-24 10:00AM	Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
07:30AM	Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis (GlobeNewswire)
06:20AM	Intellia, ReCode partner on genetic medicines for cystic fibrosis (BioPharma Dive)
Feb-14-24 07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates (GlobeNewswire) +6.92%
Feb-13-24 06:05AM	3 Gene Editing Stocks With Unprecedented Surge Potential (InvestorPlace) -10.67%
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-08-24 01:15PM	The 3 Most Undervalued Biotech Stocks to Buy in February 2024 (InvestorPlace) +5.37%
Feb-07-24 11:50AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Feb-05-24 05:25AM	A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist (Motley Fool)
Jan-31-24 05:00PM	Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine (GlobeNewswire)
12:28PM	3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential (InvestorPlace)
Jan-30-24 05:10AM	History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does. (Motley Fool) -6.07%
Jan-29-24 09:35AM	Down -19.06% in 4 Weeks, Here's Why Intellia Therapeutics, Inc. (NTLA) Looks Ripe for a Turnaround (Zacks) +6.08%
Jan-27-24 01:25PM	2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street (Motley Fool)
08:55AM	Is It Too Late to Buy Intellia Therapeutics Stock? (Motley Fool)
Jan-24-24 07:00AM	SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa (GlobeNewswire)
Jan-22-24 05:41PM	3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024 (InvestorPlace)
Jan-21-24 08:00AM	Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics (Motley Fool)
Jan-18-24 11:50AM	Is it a Good Idea to Invest in Intellia (NTLA) Stock Now? (Zacks)
Jan-13-24 06:05AM	The Top Healthcare Stocks to Buy With $100 (Motley Fool)
Jan-12-24 08:44AM	Is Intellia Therapeutics (NTLA) Stock a Solid Choice Right Now? (Zacks)
Jan-08-24 07:45AM	Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics (Motley Fool) +5.03%
05:52AM	4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 (Motley Fool)
Jan-05-24 10:04AM	Intellia Therapeutics Layoffs 2024: What to Know About the Latest NTLA Job Cuts (InvestorPlace)
Jan-04-24 04:01PM	Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones (GlobeNewswire)
12:47PM	Intellia to lay off staff, cut some early research (BioPharma Dive)
Dec-31-23 08:45AM	2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics (Motley Fool)
Dec-27-23 06:41PM	13 Most Promising Future Stocks To Buy According To Hedge Funds (Insider Monkey)
Dec-16-23 05:00AM	5 Beaten-Down Stocks That Could Soar in 2024 (Motley Fool)
Dec-13-23 05:20AM	3 Gene-Editing Stocks With the Potential to Mint Millionaires (InvestorPlace) +7.96%
Dec-12-23 06:00AM	Could Intellia Therapeutics Become the Next CRISPR Therapeutics? (Motley Fool)
Dec-10-23 11:57AM	5 Best Genomics Stocks To Buy Now (Insider Monkey)
Nov-28-23 05:30AM	2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market (Motley Fool)
Nov-24-23 07:00AM	Gene Editing Will Change Medicineand Maybe Health Investing Too (The Wall Street Journal)
Nov-15-23 11:07AM	Intellia (NTLA) Rises on EC's Orphan Drug Tag for HAE Candidate (Zacks)
Nov-14-23 07:30AM	Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (GlobeNewswire) +11.09%
Nov-10-23 05:38PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
06:30AM	Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update (Zacks)
Nov-09-23 04:06PM	Market Today: Tech Stocks Under Pressure Amid Mixed Earnings and Fed Remarks (GuruFocus.com) -12.27%
03:37PM	3 Biotech Stocks That Are Betting on the Future of Gene Editing (InvestorPlace)
08:29AM	Intellia Therapeutics Inc (NTLA) Reports Q3 2023 Financial Results and Progress in CRISPR Therapies (GuruFocus.com)
07:30AM	Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Nov-06-23 08:02AM	Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners (Investor's Business Daily)
Nov-02-23 07:00AM	Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting (GlobeNewswire)
06:45AM	1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years (Motley Fool)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
10:00AM	Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-23 07:30AM	Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy? (Motley Fool)
Oct-26-23 10:02AM	Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
07:30AM	Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November (GlobeNewswire)
Oct-23-23 09:40AM	Intellia (NTLA) Focuses on Developing Gene-Editing Therapies (Zacks)
08:45AM	3 Stocks Cathie Wood Is Buying That Should Be on Your List Too (Motley Fool)
Oct-21-23 05:00AM	Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time (Motley Fool)
Oct-19-23 11:46AM	Intellia's (NTLA) IND for Gene-Editing Therapy Gets FDA Clearance (Zacks)
Oct-18-23 04:10PM	Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing (Investor's Business Daily)
07:00AM	Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy (GlobeNewswire)
Oct-16-23 12:39PM	Intellia's (NTLA) HAE Candidate Gets EMA's PRIME Designation (Zacks)
10:43AM	16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Woods Portfolio (Insider Monkey)
Oct-14-23 12:20PM	2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years (Motley Fool)
Oct-13-23 08:38AM	Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (GlobeNewswire)
Oct-12-23 08:57AM	2 Brilliant Growth Stocks to Buy and Hold Forever (Motley Fool)
Oct-10-23 02:00PM	Down 45%, Is Intellia a Buy? (Motley Fool)

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BASTA JAMES	EVP, General Counsel	Mar 04 '24	Sale	32.99	2,297	75,778	81,571	Mar 05 04:10 PM
Clark Eliana	EVP, Chief Technical Officer	Mar 04 '24	Sale	32.99	605	19,959	71,470	Mar 05 04:10 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 08 '24	Sale	28.87	2,275	65,682	43,927	Jan 10 04:15 PM
LEONARD JOHN M	President and CEO	Jan 03 '24	Sale	29.46	19,223	566,310	846,486	Jan 05 04:51 PM
Lebwohl David	EVP, Chief Medical Officer	Jan 03 '24	Sale	29.46	5,843	172,135	54,372	Jan 05 04:50 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 03 '24	Sale	29.46	5,532	162,973	46,202	Jan 05 04:50 PM
Goddard Glenn	EVP, Chief Financial Officer	Jan 03 '24	Sale	29.46	5,365	158,053	40,585	Jan 05 04:49 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 03 '24	Sale	29.50	4,608	135,954	40,845	Jan 05 04:44 PM
Hicks Derek	EVP, Chief Business Officer	Jan 03 '24	Sale	29.46	3,877	114,216	36,987	Jan 05 04:46 PM
BASTA JAMES	EVP, General Counsel	Jan 03 '24	Sale	29.46	3,805	112,095	51,474	Jan 05 04:45 PM
Bhanji Muna	Director	Oct 31 '23	Sale	23.90	265	6,334	11,996	Nov 02 04:42 PM
Bhanji Muna	Director	Jul 31 '23	Sale	42.33	265	11,217	12,261	Aug 02 05:19 PM
Bhanji Muna	Director	Jul 06 '23	Sale	39.30	1,867	73,373	12,526	Jul 10 05:21 PM
Clark Eliana	EVP, Chief Technical Officer	Jul 03 '23	Sale	40.51	360	14,584	45,146	Jul 06 03:34 PM
Clark Eliana	EVP, Chief Technical Officer	Jun 20 '23	Option Exercise	12.27	5,000	61,350	50,146	Jun 22 05:52 PM
Clark Eliana	EVP, Chief Technical Officer	Jun 20 '23	Sale	45.00	5,000	225,000	45,146	Jun 22 05:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTLA

Intellia Therapeutics Inc

Upgrade your FINVIZ experience